SINTX rises after first use of FDA-cleared implant, names new president
Shares of biomaterials maker SINTX Technologies SINT.O rise 7% to $2.75
Co says a surgeon performed the first human surgery using its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, marking SINTX's entry into the foot and ankle reconstruction market
The system is used to correct bone alignment problems in the foot and ankle, a common issue linked to joint damage and deformities, co says
Says it also named Ryan Elmore as president to lead commercialization and revenue growth efforts
Co says it is preparing for commercial rollout of the SINAPTIC wedge system and targeting revenue growth in 2026 after streamlining operations and raising about $10 million over the past year
Says it is expanding manufacturing, including AI‑assisted 3D printing, and exploring new uses of its silicon nitride beyond implants
Share up ~10% in 2025
